doi: 10.1111/j.1463-1326.2010.01238.x 15 FangJ.-K.PrabuS
At some point, a weight loss plateau is expected
Oral administration of PF-06882961 shows evidence of glucose-lowering in healthy human study participants PF-06882961 was selected as a candidate for clinical studies based on its in vitro and in vivo pharmacologic and disposition profile, including potent agonism of the GLP-1R, preclinical disposition attributes (e.g., low metabolic CL int in human hepatocytes), good safety margins versus the hERG channel (IC 50 = 4.3 M, Table S4) and broad panel screening (Table S8), and selectivity versus related class B GPCRs (Table S9)
While the evidence for migraine prevention is promising, there are documented cases where GLP-1 agonists have made migraines worse
Why the GutMetabolism Connection Matters The gut microbiome influences many aspects of metabolic health including digestive signaling, short-chain fatty acid production, immune communication, and gut barrier integrity
The presence of a well-structured healthcare system further supports the adoption of GLP-1 therapies, making Europe a promising market for future growth